Paper40941017
Melanoma Skin Cancer: A Comprehensive Review of Current Knowledge.
Caraviello C and 8 others. Cancers (Basel), 2025. Cited by 34 papers, by iCite.
Cite this record
ConductScience Library. Melanoma Skin Cancer: A Comprehensive Review of Current Knowledge. Papers, record 40941017. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40941017
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References254
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33845460 | NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. | J Natl Compr Canc Netw | 2021 | https://conductscience.org/library/papers/33845460 | PubMed |
| 2 | 32238921 | Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. | Br J Cancer | 2020 | https://conductscience.org/library/papers/32238921 | PubMed |
| 3 | 7490362 | Lentigo maligna and lentigo maligna melanoma. | J Am Acad Dermatol | 1995 | https://conductscience.org/library/papers/7490362 | PubMed |
| 4 | 36564126 | Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/36564126 | PubMed |
| 5 | 31758078 | Melanoma pathology reporting and staging. | Mod Pathol | 2020 | https://conductscience.org/library/papers/31758078 | PubMed |
| 6 | 21102518 | Efficient in vivo microRNA targeting of liver metastasis. | Oncogene | 2011 | https://conductscience.org/library/papers/21102518 | PubMed |
| 7 | 17131335 | The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. | Int J Cancer | 2007 | https://conductscience.org/library/papers/17131335 | PubMed |
| 8 | 34986285 | Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34986285 | PubMed |
| 9 | 32015020 | Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32015020 | PubMed |
| 10 | 25727210 | Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. | J Cutan Pathol | 2015 | https://conductscience.org/library/papers/25727210 | PubMed |
| 11 | 37544359 | Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma. | J Mol Diagn | 2023 | https://conductscience.org/library/papers/37544359 | PubMed |
| 12 | 32745161 | Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis. | JAMA Dermatol | 2020 | https://conductscience.org/library/papers/32745161 | PubMed |
| 13 | 15837860 | First prospective study of the recognition process of melanoma in dermatological practice. | Arch Dermatol | 2005 | https://conductscience.org/library/papers/15837860 | PubMed |
| 14 | 15617990 | Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. | Eur J Cancer | 2005 | https://conductscience.org/library/papers/15617990 | PubMed |
| 15 | 28283772 | Identification, genetic testing, and management of hereditary melanoma. | Cancer Metastasis Rev | 2017 | https://conductscience.org/library/papers/28283772 | PubMed |
| 16 | 39709737 | European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024. | Eur J Cancer | 2025 | https://conductscience.org/library/papers/39709737 | PubMed |
| 17 | 39602056 | Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review. | Curr Oncol Rep | 2024 | https://conductscience.org/library/papers/39602056 | PubMed |
| 18 | 26819111 | Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. | J Dtsch Dermatol Ges | 2016 | https://conductscience.org/library/papers/26819111 | PubMed |
| 19 | 30422243 | Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/30422243 | PubMed |
| 20 | 37142291 | Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/37142291 | PubMed |
Cited by36
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941874 | Licochalcone A Inhibits Melanoma Cell Survival by Suppressing HSP75 (TRAP1) and Disrupting Cellular Redox and Energy Homeostasis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941874 | PubMed |
| 42929909 | Carboxymethylcellulose/Hyaluronic Acid Hybrid Nanoconjugates: Toward Multifunctional Platforms for Melanoma Skin Cancer Theranostics. | Gels | 2026 | https://conductscience.org/library/papers/42929909 | PubMed |
| 42903663 | Towards epigenetically informed and biobank-driven precision immunotherapy in melanoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42903663 | PubMed |
| 42882458 | Redox Storm in the Tumor Microenvironment (ΤΜΕ): Multifaceted Redox Injury and Immunometabolic Reprogramming Induced by Immune Checkpoint Blockade in B16F10 Melanoma: An Ultrastructural Study of the Peritumoral Interface. | Cells | 2026 | https://conductscience.org/library/papers/42882458 | PubMed |
| 42795718 | Melanoma Intelligence: Explainable AI Reveals Histopathologic Aggressiveness as the Dominant Axis of Lymph-Node Metastasis. | J Clin Med | 2026 | https://conductscience.org/library/papers/42795718 | PubMed |
| 42756612 | Molecular reprogramming in cutaneous melanoma: the central role of G9a and EZH2 methyltransferase inhibitors in tumor plasticity, immune evasion, and therapeutic resistance. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42756612 | PubMed |
| 42738249 | The Role of Transcriptional and Atypical Cyclin-Dependent Protein Kinases in Melanoma. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738249 | PubMed |
| 42649762 | Automated Skin Lesion and Cancer Detection Using Computer Vision: A Comprehensive Review. | Bioengineering (Basel) | 2026 | https://conductscience.org/library/papers/42649762 | PubMed |
| 42588706 | Predictive Biomarkers of Systemic Therapy Response in Cutaneous Melanoma. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588706 | PubMed |
| 42512381 | Unravelling the Intricate Mechanism of Cucurbitacin-Mediated Anti-Cancer Therapy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512381 | PubMed |
| 42509856 | Interaction of Alkannin with CPEB4 Contributes to Its Antitumor Effects in Melanoma. | Biomolecules | 2026 | https://conductscience.org/library/papers/42509856 | PubMed |
| 42500571 | Epigenetic Modulators and Immunotherapy in Malignant Melanoma. | Oncol Res | 2026 | https://conductscience.org/library/papers/42500571 | PubMed |
| 42439659 | Reshaping the Battlefield: Reprogramming the Melanoma Tumour Microenvironment (TME) by Anti-CTLA-4, Anti-PD-1, and Anti-PD-L1 Monotherapy and Combination Therapy: A Systematic Review and Meta-Analysis of Preclinical and Clinical Evidence. | Cells | 2026 | https://conductscience.org/library/papers/42439659 | PubMed |
| 42358547 | Multimodal treatment and long-term survival in a rare case of melanoma with pancreatic and splenic metastases: a case report and literature review. | Front Oncol | 2026 | https://conductscience.org/library/papers/42358547 | PubMed |
| 42356529 | Immunosuppressive Pathways in Cutaneous Melanoma: Functional Integration Between PD-1 and CD73 and Therapeutic Implications. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42356529 | PubMed |
| 42352510 | Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42352510 | PubMed |
| 42318376 | Skin Cancer in the Rural South: Strengthening Dermatologic Training for Frontline Primary Care. | Cureus | 2026 | https://conductscience.org/library/papers/42318376 | PubMed |
| 42282857 | Sarcoidosis-Like Granulomatous Reaction During Adjuvant Pembrolizumab for High-Risk Resected Melanoma. | Case Rep Oncol Med | 2026 | https://conductscience.org/library/papers/42282857 | PubMed |
| 42262336 | Melanoma in an Unlikely Guise: Diagnostic Challenges of a Solid-cystic Popliteal Mass in Neurofibromatosis Type 1. | Ann Afr Med | 2026 | https://conductscience.org/library/papers/42262336 | PubMed |
| 42243532 | PLD1 and PLD2 promote an immunosuppressive tumor microenvironment via CCL19-dependent macrophage polarization and PD-L1 induction. | Exp Mol Med | 2026 | https://conductscience.org/library/papers/42243532 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40941017
GET https://conductscience.org/api/papers/v1/40941017/references?page=2